Carregant...
ANGI-10. WSD1227: A BRAIN PENETRABLE VEGFR2 INHIBITOR FOR THE TREATMENT OF PRIMARY AND METASTATIC BRAIN TUMORS
The VEGF pathway has emerged as an important target for cancer therapy by blocking the development of malignant neovasculature, thus to reduce oxygen availability to the tumor and decrease its growth. Anti-VEGF agents have been approved for several malignancies, such as GBM, NSCLC, mBC, CRC, OC, etc...
Guardat en:
| Publicat a: | Neuro Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217140/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.111 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|